Cited 0 times in Scipus Cited Count

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)

DC Field Value Language
dc.contributor.authorPark, JS-
dc.contributor.authorShin, JH-
dc.contributor.authorHong, TJ-
dc.contributor.authorSeo, HS-
dc.contributor.authorShim, WJ-
dc.contributor.authorBaek, SH-
dc.contributor.authorJeong, JO-
dc.contributor.authorAhn, Y-
dc.contributor.authorKang, WC-
dc.contributor.authorKim, YH-
dc.contributor.authorKim, SH-
dc.contributor.authorHyon, MS-
dc.contributor.authorChoi, DH-
dc.contributor.authorNam, CW-
dc.contributor.authorPark, TH-
dc.contributor.authorLee, SC-
dc.contributor.authorKim, HS-
dc.date.accessioned2018-05-04T00:24:41Z-
dc.date.available2018-05-04T00:24:41Z-
dc.date.issued2016-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14889-
dc.description.abstractThe pill burden of patients with hypertension and dyslipidemia can result in poor medication compliance. This study aimed to evaluate the efficacy and safety of fixed-dose combination (FDC) therapy with olmesartan medoxomil (40 mg) and rosuvastatin (20 mg) in Korean patients with mild to moderate hypertension and dyslipidemia. This multicenter, randomized, double-blind, factorial-design study included patients aged >/=20 years with mild to moderate essential hypertension and dyslipidemia. Patients were randomly assigned to receive FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin), 40 mg olmesartan medoxomil, 20 mg rosuvastatin, or a placebo. The percentage change from baseline in low-density lipoprotein cholesterol levels was compared between FDC therapy and olmesartan medoxomil, and the change from baseline in diastolic blood pressure was compared between FDC therapy and rosuvastatin 8 weeks after treatment. A total of 162 patients were included. The least square mean percentage change (standard error) from baseline in low-density lipoprotein cholesterol levels 8 weeks after treatment was significantly greater in the FDC than in the olmesartan medoxomil group (-52.3% [2.8%] vs -0.6% [3.5%], P<0.0001), and the difference was -51.7% (4.1%) (95% confidence interval: -59.8% to -43.6%). The least square mean change (standard error) from baseline in diastolic blood pressure 8 weeks after treatment was significantly greater in the FDC group than in the rosuvastatin group (-10.4 [1.2] mmHg vs 0.1 [1.6] mmHg, P<0.0001), and the difference was -10.5 (1.8) mmHg (95% confidence interval: -14.1 to -6.9 mmHg). There were 50 adverse events in 41 patients (22.7%) and eight adverse drug reactions in five patients (2.8%). The study found that FDC therapy with olmesartan medoxomil and rosuvastatin is an effective, safe treatment for patients with hypertension and dyslipidemia. This combination may improve medication compliance in patients with a large pill burden.-
dc.language.isoen-
dc.subject.MESHAntihypertensive Agents-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Combinations-
dc.subject.MESHDyslipidemias-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHypertension-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOlmesartan Medoxomil-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRosuvastatin Calcium-
dc.titleEfficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong)-
dc.typeArticle-
dc.identifier.pmid27574399-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993275/-
dc.contributor.affiliatedAuthor박, 진선-
dc.contributor.affiliatedAuthor신, 준한-
dc.type.localJournal Papers-
dc.identifier.doi10.2147/DDDT.S112873-
dc.citation.titleDrug design, development and therapy-
dc.citation.volume10-
dc.citation.date2016-
dc.citation.startPage2599-
dc.citation.endPage2609-
dc.identifier.bibliographicCitationDrug design, development and therapy, 10. : 2599-2609, 2016-
dc.identifier.eissn1177-8881-
dc.relation.journalidJ011778881-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
Files in This Item:
27574399.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse